表紙
市場調査レポート

2017年までの凝固障害市場:特許失効と脆弱なパイプラインにより最大セグメントの血友病Aの成長率が低下見込み

Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

発行 GBI Research 商品コード 214251
出版日 ページ情報 英文 114 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
2017年までの凝固障害市場:特許失効と脆弱なパイプラインにより最大セグメントの血友病Aの成長率が低下見込み Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
出版日: 2011年09月17日 ページ情報: 英文 114 Pages
概要

世界の凝固障害市場は2002〜2010年の成長市場のひとつでした。しかし今後、多くの疾患セグメントで特許が失効し、ジェネリック薬が代用されるなど、将来的な市場成長は鈍化するものとみられています。にもかかわらず、同市場は今後7年間はゆるやかに成長を続けると予測されています。2010年、市場は56億米ドル規模となり、2002〜2010年のCAGRは6.7%でしたが、2017年までに83億米ドルに達する見通しです。

当レポートでは、世界の凝固障害市場について調査分析し、疾患の概要と地域別動向、治療環境、パイプライン動向、参入企業の競合プロファイルなどをまとめ、概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 世界の凝固障害市場の収益予測
    • 収益
    • 年間治療費
    • 治療使用形態
  • 凝固障害市場促進因子
    • 特に欧州5カ国における安定した有病患者人口の増加
    • 有効性、安全性、利便性により組み替え製品が急速に摂取される
    • 高価な生物製剤の特許失効によりより値ごろな価格となり処方人口が増加する
  • 凝固障害市場阻害因子
    • 軽度〜中等度の凝固障害患者が診断を受けていないことにより診断人口が低下
    • 主なブロックバスター薬の特許失効
    • 年間治療費の成長鈍化

第4章 地域別環境

  • 地域別内訳
  • 米国
  • 欧州主要5カ国
  • 日本

第5章 治療環境

  • 血友病A
  • 血友病B
  • フォン・ヴィレブランド病
    • イントロダクション
    • 収益
    • 年間治療費
    • 疫学
    • 現在の使用
    • 地域別セグメンテーション

第6章 パイプライン分析

  • イントロダクション
  • 凝固障害市場における後期段階薬剤プロファイル

第7章 競合環境

  • 競合プロファイリング
    • Baxter International Inc
    • Novo Nordisk A/S
    • Pfizer Inc
    • CSL Behring LLC
    • Bayer AG
    • LFB
    • Grifols
    • Biotest
    • Bio Product Laboratory
    • Octapharma

第8章 戦略的考察

  • 概要
    • 地域別取引
    • 金額別取引

第9章 付録

図表

目次
Product Code: GBIHC074MR

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline", provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2016 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.

Scope

The scope of this report includes -

  • Annualized market data for the coagulation disorders market from 2002 to 2010, forecast forward to 2017.
  • Analysis of the leading therapeutic segments, including hemophilia A, hemophilia B, and von Willebrand's disease (vWD).
  • Analysis of the coagulation disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the coagulation disorders market, including market size, annual cost of therapy and treatment usage patterns.
  • Key drivers and barriers that have a significant impact on the market.
  • Coverage of pipeline molecules in various phases of drug development.
  • Competitive benchmarking of leading companies. The key companies studied in this report are Baxter International Inc, Bayer AG, Novo Nordisk A/S, Pfizer Inc and CSL Behring LLC.
  • Key M&A activities and licensing agreements that have taken place between 2004 and 2010 in the global coagulation disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with higher efficiency and better safety.
  • Develop strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Companies Mentioned

  • Baxter International Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • CSL Behring LLC
  • Bayer AG
  • LFB
  • Grifols
  • Biotest
  • Bio Product Laboratory
  • Octapharma

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 6
  • 1.2 List of Figures 7

2 Introduction 9

  • 2.1 GBI Research Report Guidance 9

3 Coagulation Disorders Therapeutics Market: Market Overview 10

  • 3.1 Introduction 10
  • 3.2 Revenue Forecasts for the Global Coagulation Disorders Market 11
    • 3.2.1 Revenue 11
    • 3.2.2 Annual Cost of Therapy 12
    • 3.2.3 Treatment Usage Pattern 13
  • 3.3 Coagulation Disorders Market Drivers 19
    • 3.3.1 Steady Increase in the Prevalence Population, Particularly in the Top Five Countries in Europe 19
    • 3.3.2 Rapid Uptake of Recombinant Products due to Better Efficacy, Safety and Convenient Dosing 19
    • 3.3.3 Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable 20
  • 3.4 Coagulation Disorders Market Restraints 21
    • 3.4.1 Low Diagnosed Population as Mild and Moderate Forms of Coagulation Disorders Go Undiagnosed 21
    • 3.4.2 Patent Expiries of Major Blockbusters Including Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market 21
    • 3.4.3 Sluggish Growth in the Annual Cost of Therapy for Coagulation Disorders is Expected to Drive Down the Growth Rate 21

4 Global Coagulation Disorders Market: Geographical Landscape 22

  • 4.1 Geographical Break-up 22
  • 4.2 The US 24
    • 4.2.1 Revenue 24
    • 4.2.2 Annual Cost of Therapy 25
    • 4.2.3 Treatment Usage Patterns 26
  • 4.3 Top Five Countries in Europe 29
    • 4.3.1 Revenue 29
    • 4.3.2 Annual Cost of Therapy 30
    • 4.3.3 Treatment Usage Pattern 31
  • 4.4 Japan 34
    • 4.4.1 Revenue 34
    • 4.4.2 Annual Cost of Therapy 35
    • 4.4.3 Treatment Usage Patterns 36

5 Coagulation Disorders Therapeutics Market: Therapeutic Landscape 38

  • 5.1 Hemophilia A Market 38
    • 5.1.1 Introduction 38
    • 5.1.2 Revenue 41
    • 5.1.3 Annual Cost of Treatment 45
    • 5.1.4 Treatment Flow Algorithm 46
    • 5.1.5 Treatment Usage Pattern 47
  • 5.2 Hemophilia B Market 50
    • 5.2.1 Introduction 50
    • 5.2.2 Revenue 53
    • 5.2.3 Annual Cost of Treatment 56
    • 5.2.4 Treatment Flow Algorithm 57
    • 5.2.5 Treatment Usage Pattern 58
  • 5.3 von Willebrand Disease (vWD) Market 60
    • 5.3.1 Introduction 60
    • 5.3.2 Revenue 65
    • 5.3.3 Annual Cost of Treatment 68
    • 5.3.4 Treatment Flow Algorithm 69
    • 5.3.5 Treatment Usage Pattern 70

6 Coagulation Disorders Therapeutics Market to 2017: Pipeline Analysis 73

  • 6.1 Introduction 73
    • 6.1.1 Research and Development Pipeline - Hemophilia 74
    • 6.1.2 Research and Development Pipeline - von Willebrand Disease (vWD) 77
  • 6.2 Profiles of Key Late-Stage Drugs in the Coagulation Disorders Market 78
    • 6.2.1 NecLip-pdFVIII 78
    • 6.2.2 Long Acting rFactor VIII 78
    • 6.2.3 OBI-1 79
    • 6.2.4 Recombinant Factor IX Fc Fusion Protein (rFIXFc) 80
    • 6.2.5 NN7008 81
    • 6.2.6 Human-cl rhFVIII 81
    • 6.2.7 BAX 326 82
    • 6.2.8 IB1001 83
    • 6.2.9 NNC-0156-0000-0009 84
    • 6.2.10 Biostate 84
    • 6.2.11 Long Acting rFactor IX 85

7 Global Coagulation Disorders Market: Competitive Landscape 87

  • 7.1 Competitive Profiling 87
    • 7.1.1 Baxter International Inc. 87
    • 7.1.2 Novo Nordisk A/S 89
    • 7.1.3 Pfizer Inc. 91
    • 7.1.4 CSL Behring LLC 93
    • 7.1.5 Bayer AG 94
    • 7.1.6 LFB 95
    • 7.1.7 Grifols 96
    • 7.1.8 Biotest 99
    • 7.1.9 Bio Product Laboratory 100
    • 7.1.10 Octapharma 101

8 Global Coagulation Disorders Market: Strategic Consolidations 104

  • 8.1 Overview 104
    • 8.1.2 Deals by Geography 106
    • 8.1.3 Deals by Value ($) 107

9 Global Coagulation Disorders Market: Appendix 108

  • 9.1 Market Definitions 108
  • 9.2 Abbreviations 108
  • 9.3 Research Methodology 109
    • 9.3.1 Coverage 109
    • 9.3.2 Secondary Research 109
    • 9.3.3 Primary Research 110
  • 9.4 Therapeutic Landscape 110
    • 9.4.2 Market Size by Geography 112
  • 9.5 Geographical Landscape 113
  • 9.6 Pipeline Analysis 113
  • 9.7 Competitive Landscape 113
    • 9.7.1 Expert Panel Validation 113
  • 9.8 Contact Us 113
  • 9.9 Disclaimer 113
  • 9.10 Sources 114

List of Tables

  • Table 1: Coagulation Disorders Market, Global, Revenue ($bn), 2002-2010 11
  • Table 2: Coagulation Disorders Market, Global, Revenue ($bn), 2010-2017 11
  • Table 3: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010 12
  • Table 4: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017 12
  • Table 5: Coagulation Disorders Market, Global, Treatment Usage Patterns (thousands), 2002-2010 13
  • Table 6: Coagulation Disorders Market, Global, Treatment Usage Patterns (thousands), 2010-2017 14
  • Table 7: Coagulation Disorders Market, Global, Sales Value by Geography ($bn), 2002-2010 22
  • Table 8: Coagulation Disorders Market, Global, Sales Value by Geography ($bn), 2010-2017 23
  • Table 9: Coagulation Disorders Market, The US, Revenue ($bn), 2002-2010 24
  • Table 10: Coagulation Disorders Market, The US, Sales Value ($bn), 2010-2017 24
  • Table 11: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2002-2010 25
  • Table 12: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2010-2017 25
  • Table 13: Coagulation Disorders Market, The US, Treatment Usage Pattern (thousands), 2002-2010 27
  • Table 14: Coagulation Disorders Market, The US, Treatment Usage Pattern (thousands), 2010-2017 27
  • Table 15: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010 29
  • Table 16: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2010-2017 29
  • Table 17: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002-2010 30
  • Table 18: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 30
  • Table 19: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (thousands), 2002-2010 31
  • Table 20: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (thousands), 2010-2017 32
  • Table 21: Coagulation Disorders Market, Japan, Revenue ($m), 2002-2010 34
  • Table 22: Coagulation Disorders Market, Japan, Revenue ($m), 2010-2017 34
  • Table 23: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2010 35
  • Table 24: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2010-2017 35
  • Table 25: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousands), 2002-2010 36
  • Table 26: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousand), 2010-2017 37
  • Table 27: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002-2010 42
  • Table 28: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2010-2017 42
  • Table 29: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 45
  • Table 30: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 45
  • Table 31: Hemophilia A Therapeutics Market, Global Treatment Usage Pattern (thousand), 2002-2010 48
  • Table 32: Hemophilia A Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010-2017 48
  • Table 33: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002-2010 53
  • Table 34: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2010-2017 53
  • Table 35: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 56
  • Table 36: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 56
  • Table 37: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002-2010 58
  • Table 38: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010-2017 59
  • Table 39: vWD Therapeutics Market, Global, Revenue ($m), 2002-2010 65
  • Table 40: vWD Therapeutics Market, Global, Revenue ($m), 2010-2017 65
  • Table 41: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 68
  • Table 42: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 68
  • Table 43: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002-2010 70
  • Table 44: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2010-2017 71
  • Table 45: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase, 2011 75
  • Table 46: vWD Therapeutics Market, Global, R&D Pipeline by Phase 77
  • Table 47: Coagulation Disorders Market, Global, Major M&A Deals, 2008-2010 105

List of Figures

  • Figure 1: Coagulation Disorders Market, Global, Drivers and Restraints, 2010 10
  • Figure 2: Coagulation Disorders Market, Global, Revenue ($bn), 2002-2017 11
  • Figure 3: Coagulation Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017 12
  • Figure 4: Coagulation Disorders Market, Global, Treatment Usage Pattern (thousands), 2002-2017 13
  • Figure 5: Coagulation Disorders Market, Global, Diseased Population (thousands), 2002-2017 15
  • Figure 6: Coagulation Disorders Market, Global, Treatment Seeking Population (thousands), 2002-2017 16
  • Figure 7: Coagulation Disorders Market, Global, Diagnosed Population (thousands), 2002-2017 17
  • Figure 8: Coagulation Disorders Market, Global, Prescription Population (thousands), 2002-2017 18
  • Figure 9: Coagulation Disorders Market, Global, Market Indicators, 2010 20
  • Figure 10: Coagulation Disorders Market, Global, Market Share by Geography ($bn), 2002-2017 22
  • Figure 11: Coagulation Disorders Market, The US, Sales Value ($bn), 2002-2017 24
  • Figure 12: Coagulation Disorders Market, The US, Annual Cost of Treatment ($), 2002-2017 25
  • Figure 13: Coagulation Disorders Market, The US, Treatment Usage Patterns (thousands), 2002-2017 26
  • Figure 14: Coagulation Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2017 29
  • Figure 15: Coagulation Disorders Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2002-2017 30
  • Figure 16: Coagulation Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (thousands), 2002-2017 31
  • Figure 17: Coagulation Disorders Market, Japan, Revenue ($m), 2002-2017 34
  • Figure 18: Coagulation Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2017 35
  • Figure 19: Coagulation Disorders Market, Japan, Treatment Usage Pattern (thousand), 2002-2017 36
  • Figure 20: Hemophilia A Therapeutics Market, Hemophilia - Disease Cause, 2011 38
  • Figure 21: Hemophilia A Therapeutics Market, Global, Revenue ($bn), 2002-2017 41
  • Figure 22: Hemophilia A Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 43
  • Figure 23: Hemophilia A Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 44
  • Figure 24: Hemophilia A Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 45
  • Figure 25: Hemophilia A Therapeutics Market, Global, Treatment Flow Algorithm 46
  • Figure 26: Hemophilia A Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002-2017 47
  • Figure 27: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2002-2017 53
  • Figure 28: Hemophilia B Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 54
  • Figure 29: Hemophilia B Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 55
  • Figure 30: Hemophilia B Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 56
  • Figure 31: Hemophilia B Therapeutics Market, Global, Treatment Flow Algorithm 57
  • Figure 32: Hemophilia B Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002-2017 58
  • Figure 33: vWD Therapeutics Market, Global, Revenue ($m), 2002-2017 65
  • Figure 34: vWD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 66
  • Figure 35: vWD Therapeutics Market, Global, Revenue Segmentation (%), 2010 and 2017 67
  • Figure 36: vWD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 68
  • Figure 37: vWD Therapeutics Market, Global, Treatment Flow Algorithm 69
  • Figure 38: vWD Therapeutics Market, Global, Treatment Usage Pattern (thousand), 2002-2017 70
  • Figure 39: Coagulation Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), Jul 2011 73
  • Figure 40: Hemophilia Therapeutics Market, Global, R&D Pipeline by Phase (%), Jul 2011 74
  • Figure 41: vWD Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77
  • Figure 42: Coagulation Disorders Market, Global, SWOT - Baxter International Inc, 2011 89
  • Figure 43: Coagulation Disorders Market, Global, SWOT - Novo Nordisk, 2011 91
  • Figure 44: Coagulation Disorders Market, Global, SWOT - Pfizer, 2011 92
  • Figure 45: Coagulation Disorders Market, Global, SWOT - CSL Behring, 2011 94
  • Figure 46: Coagulation Disorders Market, Global, SWOT - Bayer AG, 2011 95
  • Figure 47: Coagulation Disorders Market, Global, SWOT - Laboratoire franCais du Fractionnement et des Biotechnologies, 2011 96
  • Figure 48: Coagulation Disorders Market, Global, SWOT - Grifols, 2011 99
  • Figure 49: Coagulation Disorders Market, Global, SWOT - Biotest, 2011 100
  • Figure 50: Coagulation Disorders Market, Global, SWOT - Bio Products Laboratory, 2011 101
  • Figure 51: Coagulation Disorders Market, Global, SWOT - Octapharma AG, 2011 103
  • Figure 52: Coagulation Disorders Market, Global, Deals by Indication (%), 2004-2010 104
  • Figure 53: Coagulation Disorders Market, Global, Major Licensing Agreements by Geography (%), 2004-2010 106
  • Figure 54: Coagulation Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004-2010 107
  • Figure 55: GBI Research Market Forecasting Model 112
Back to Top